Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04585490 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Aug 2026 → Dec 2026
See other at-risk trials from Stanford University

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Maximilian Diehn to Stanford University Show 4 more changesShow less
    • Primary completion pushed from Aug 2026 to Dec 2026
    • Eligibility criteria expanded, about 35 words
    • Secondary endpoints: details revised at 4 of 4 entries
    • Study title shortened, about 7 words
  2. Primary completion date: Apr 1, 2026 to Aug 2026
    • Study completion date: Apr 1, 2028 to Apr 2028
    v9
  3. Re-verified, no change to tracked fieldsv8
  4. Primary completion date: Mar 2024 to Apr 1, 2026v7 Show 5 more changesShow less
    • Study completion date: Mar 2026 to Apr 1, 2028
    • Interventions: AVENIO ctDNA Surveillance Kit (Device), Carboplatin (Drug), Cisplatin (Drug), Durvalumab (Drug), Paclitaxel (Drug), Pemetrexed (Drug) to AVENIO ctDNA Surveillance Kit (Device), Carboplatin (Drug), Cisplatin (Drug), Durvalumab (Drug), Paclitaxel (Drug), Pemetrexed (Drug)…
    • Eligibility criteria expanded, about 84 words
    • Secondary endpoints revised (4)
    • Study description shortened, about 4 words
  5. Re-verified, no change to tracked fieldsv6
Show 4 earlier versionsHide 4 earlier versions
  1. Lead sponsor: Joel Neal to Maximilian Diehnv5
  2. Lead sponsor: Stanford University to Joel Neal
    • Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 2021 to Aug 25, 2021
    • Site details revised
    v4
  3. Start date: Mar 2021 to Oct 2021v3
  4. Primary endpoint revisedv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to test whether or not number of circulating cancer cells detected in the blood can be decreased the by combining the standard treatment (durvalumab) with Tremelimumab and additional chemotherapy
Trial Details
NCT Number NCT04585490
Lead Sponsor Stanford University
Collaborators: AstraZeneca
Conditions
(from sponsor)		 Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov